## Elisa Passini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7236666/publications.pdf Version: 2024-02-01



FLIGA DAGGINI

#	Article	IF	CITATIONS
1	Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Frontiers in Physiology, 2017, 8, 668.	2.8	227
2	Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm. Progress in Biophysics and Molecular Biology, 2016, 120, 115-127.	2.9	141
3	Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. ELife, 2019, 8, .	6.0	131
4	Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2016, 96, 72-81.	1.9	102
5	Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior. Physiological Reviews, 2021, 101, 1083-1176.	28.8	87
6	General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA <i>In Silico</i> Strategy. Clinical Pharmacology and Therapeutics, 2020, 107, 102-111.	4.7	67
7	Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach. Heart Rhythm, 2017, 14, 1704-1712.	0.7	54
8	Drugâ€induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias. British Journal of Pharmacology, 2019, 176, 3819-3833.	5.4	47
9	All-Optical Electrophysiology Refines Populations of In Silico Human iPSC-CMs for Drug Evaluation. Biophysical Journal, 2020, 118, 2596-2611.	0.5	40
10	Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis. Europace, 2014, 16, 396-404.	1.7	30
11	Human Purkinje in silico model enables mechanistic investigations into automaticity and pro-arrhythmic abnormalities. Journal of Molecular and Cellular Cardiology, 2020, 142, 24-38.	1.9	29
12	Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk Assessment. Frontiers in Pharmacology, 2019, 10, 1643.	3.5	26
13	Simulation of the Effects of Extracellular Calcium Changes Leads to a Novel Computational Model of Human Ventricular Action Potential With a Revised Calcium Handling. Frontiers in Physiology, 2020, 11, 314.	2.8	26
14	Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used offâ€label in the first wave of COVIDâ€19. Clinical and Translational Science, 2021, 14, 1133-1146.	3.1	23
15	Comparison of the Simulated Response of Three in Silico Human Stem Cell-Derived Cardiomyocytes Models and in Vitro Data Under 15 Drug Actions. Frontiers in Pharmacology, 2021, 12, 604713.	3.5	15
16	The virtual assay software for human in silico drug trials to augment drug cardiac testing. Journal of Computational Science, 2021, 52, 101202.	2.9	14
17	Human Atrial Cell Models to Analyse Haemodialysis-Related Effects on Cardiac Electrophysiology: Work in Progress. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-18.	1.3	7
18	Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay. Toxicology and Applied Pharmacology, 2020, 390, 114883.	2.8	6

#	Article	IF	CITATIONS
19	In Silico Identification of the Key Ionic Currents Modulating Human Pluripotent Stem Cell-Derived Cardiomyocytes Towards an Adult Phenotype. , 2021, , .		2